[Edaily Starin Gim Ga Yeong Reporter] Netflix’s variety show “Born Single, But I Want to Date” (“Born Single, But I Want to Date”) has confirmed production of Season 3. Photo courtesy of Netflix
Netflix announced the production of Season 3 of “Born Single, But Wanting a Relationship” on the 19th. Producer Kim No-eun, who has helmed the show through Seasons 1 and 2 and will continue into Season 3, said, “Thank you for cheering on the lifelong singles as they embarked on their first-ever romantic adventures throughout Seasons 1 and 2. It feels like the production team is growing alongside the show.” She added, “We’ve listened carefully to the diverse feedback we’ve received, and we’ll return with stories that are even more authentic and full of laughter.” “First-Time Dating” is a show that follows the first romantic journeys of lifelong singles who have zero experience but the highest hopes. With the production confirmed, the show is now recruiting lifelong singles to embark on their first-ever romantic adventures. “Lifelong Singles’ Love” has opened a new chapter in dating reality TV with the love journeys of lifelong singles who may be clumsy but are more sincere about love than anyone else. In particular, as they watched the “lifelong singles” with no dating experience, panelists Seo In-guk, Kang Han-na, Lee Eun-ji, and KARD Garden offered heartfelt advice, and even viewers became deeply immersed, experiencing emotions unlike those found in other dating shows. The show garnered a positive response thanks to the unique entertainment value found only in “Born-Single Dating” and even achieved the remarkable feat of winning the Best Variety Program award at the 5th Blue Dragon Series Awards. Interest in Season 3 is bound to rise as a result. Meanwhile, “Single’s Dating 3” will begin casting on the 19th.
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…